Lv11
40 积分 2025-12-15 加入
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
5小时前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
9天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
21天前
已完结
Toxicologic Pathology Forum*: Opinion on Qualitative Severity Descriptors to Express Magnitude of Changes in Clinical Pathology Endpoints in Nonclinical Toxicity Studies
4个月前
已完结
皖公网安备34019202002308
